IL156264A0 - Isoindolin-1-one glucokinase activators - Google Patents

Isoindolin-1-one glucokinase activators

Info

Publication number
IL156264A0
IL156264A0 IL15626401A IL15626401A IL156264A0 IL 156264 A0 IL156264 A0 IL 156264A0 IL 15626401 A IL15626401 A IL 15626401A IL 15626401 A IL15626401 A IL 15626401A IL 156264 A0 IL156264 A0 IL 156264A0
Authority
IL
Israel
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
IL15626401A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL156264A0 publication Critical patent/IL156264A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IL15626401A 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators IL156264A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (1)

Publication Number Publication Date
IL156264A0 true IL156264A0 (en) 2004-01-04

Family

ID=26944583

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15626401A IL156264A0 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Country Status (36)

Country Link
US (1) US6482951B2 (xx)
EP (1) EP1349856B1 (xx)
JP (1) JP4021766B2 (xx)
KR (1) KR100520651B1 (xx)
CN (1) CN1247574C (xx)
AT (1) ATE297922T1 (xx)
AU (2) AU2002238415B2 (xx)
BG (1) BG107903A (xx)
BR (1) BR0116169A (xx)
CA (1) CA2430579C (xx)
CY (1) CY1105587T1 (xx)
CZ (1) CZ20031882A3 (xx)
DE (1) DE60111570T2 (xx)
DK (1) DK1349856T3 (xx)
EG (1) EG24358A (xx)
ES (1) ES2243578T3 (xx)
HK (1) HK1063314A1 (xx)
HR (1) HRP20030450B1 (xx)
HU (1) HUP0400587A3 (xx)
IL (2) IL156264A0 (xx)
MA (1) MA26973A1 (xx)
MX (1) MXPA03005170A (xx)
MY (1) MY136741A (xx)
NO (1) NO325810B1 (xx)
NZ (1) NZ526236A (xx)
PA (1) PA8534601A1 (xx)
PE (1) PE20020593A1 (xx)
PL (1) PL366006A1 (xx)
PT (1) PT1349856E (xx)
RS (1) RS50933B (xx)
RU (1) RU2249590C2 (xx)
SI (1) SI1349856T1 (xx)
SK (1) SK8732003A3 (xx)
TW (1) TWI294876B (xx)
UY (1) UY27069A1 (xx)
WO (1) WO2002048106A2 (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP4700684B2 (ja) 2004-04-02 2011-06-15 ノバルティス アーゲー 2型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
CA2561157A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
US20090281142A1 (en) * 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007053657A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2007143434A2 (en) * 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008111473A1 (ja) 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
MX2010007926A (es) * 2008-01-24 2010-08-09 Merck Patent Gmbh Derivados de beta-aminoacidos.
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
NZ589084A (en) * 2008-05-16 2012-06-29 Takeda San Diego Inc Glucokinase activators
AP2011005613A0 (en) * 2008-09-11 2011-04-30 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators.
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
DK3004076T3 (da) * 2013-05-27 2020-01-02 Hoffmann La Roche Nye 3,4-dihydro-2h-isoquinolin-1-on- og 2,3-dihydro-isoindol-1-on-forbindelser
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
KR100455635B1 (ko) 1999-03-29 2004-11-06 에프. 호프만-라 로슈 아게 글루코키나제 활성화제
CN1209361C (zh) 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren

Also Published As

Publication number Publication date
IL156264A (en) 2010-11-30
YU47703A (xx) 2006-05-25
SI1349856T1 (en) 2005-10-31
EP1349856A2 (en) 2003-10-08
CN1247574C (zh) 2006-03-29
HRP20030450A2 (en) 2005-04-30
CY1105587T1 (el) 2010-07-28
PT1349856E (pt) 2005-09-30
HUP0400587A2 (hu) 2004-06-28
AU2002238415B2 (en) 2007-01-04
US20020082260A1 (en) 2002-06-27
AU3841502A (en) 2002-06-24
HUP0400587A3 (en) 2011-03-28
JP4021766B2 (ja) 2007-12-12
PE20020593A1 (es) 2002-07-06
ATE297922T1 (de) 2005-07-15
SK8732003A3 (en) 2004-04-06
MXPA03005170A (es) 2003-09-22
PL366006A1 (en) 2005-01-24
KR100520651B1 (ko) 2005-10-11
CN1481382A (zh) 2004-03-10
HRP20030450B1 (en) 2006-02-28
RU2249590C2 (ru) 2005-04-10
NZ526236A (en) 2004-12-24
CZ20031882A3 (cs) 2003-12-17
MY136741A (en) 2008-11-28
KR20030064817A (ko) 2003-08-02
MA26973A1 (fr) 2004-12-20
CA2430579C (en) 2010-01-26
ES2243578T3 (es) 2005-12-01
WO2002048106A2 (en) 2002-06-20
UY27069A1 (es) 2002-07-31
US6482951B2 (en) 2002-11-19
HK1063314A1 (en) 2004-12-24
JP2004521095A (ja) 2004-07-15
DE60111570D1 (de) 2005-07-21
DK1349856T3 (da) 2005-10-17
WO2002048106A3 (en) 2002-11-28
NO325810B1 (no) 2008-07-21
PA8534601A1 (es) 2002-08-26
EG24358A (en) 2009-03-04
BG107903A (bg) 2004-02-27
BR0116169A (pt) 2003-12-23
RS50933B (sr) 2010-08-31
DE60111570T2 (de) 2006-05-11
NO20032674D0 (no) 2003-06-12
TWI294876B (en) 2008-03-21
EP1349856B1 (en) 2005-06-15
NO20032674L (no) 2003-06-12
CA2430579A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MY136926A (en) Glucokinase activators
WO2001083465A3 (en) Alkynyl phenyl heteroaromatic glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
JO2180B1 (en) Glucokinase Trans olivine steroids
IL144948A0 (en) Electroactive pore
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
UA84025C2 (xx) СПОЛУКИ 2-(ХІНОКСАЛІН-5-ІЛСУЛЬФОНІЛАМІНО)-БЕНЗАМІДУ ЯК МОДУЛЯТОРИ ССК2$Normal;heading 1;heading 2;СОЕДИНЕНИЯ 2-(ХИНОКСАЛИН-5-ИЛСУЛЬФОНИЛАМИНО)-БЕНЗАМИДА КАК МОДУЛЯТОРЫ ССК2
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
RS20050733A (xx) Jedinjenja benzo /1,2,5/tiadiazola
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (en) NEW USE OF PRODIGIOSIN FOR THE TREATMENT OF DIABETES MELLITUS
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
MD1919G2 (ro) Remediu medicamentos
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
ZA200107918B (en) The treatment of rubber.